Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1992 Oct;107(2):584–590. doi: 10.1111/j.1476-5381.1992.tb12787.x

Inhibition by phosphoramidon of the regional haemodynamic effects of proendothelin-2 and -3 in conscious rats.

S M Gardiner 1, P A Kemp 1, T Bennett 1
PMCID: PMC1907896  PMID: 1422599

Abstract

1. Regional haemodynamic studies were carried out in conscious, Long Evans rats, chronically-instrumented with pulsed Doppler flow probes and intravascular catheters. 2. In the first experiment, proendothelin-2 and -3 (0.1 and 1.0 nmol kg-1, i.v. boluses) were found to cause dose-dependent pressor, bradycardic, and renal and, particularly, mesenteric vasoconstrictor effects. The hindquarters showed an initial vasodilatation (which was not dose-dependent) followed by a vasoconstriction (which was dose-related). The pressor and renal and mesenteric vasoconstrictor effects of proendothelin-3 were greater than those of proendothelin-2. 3. In the second experiment, it was demonstrated that phosphoramidon (10 mumol kg-1, i.v. bolus) abolished the pressor, bradycardiac, and hindquarters vasoconstrictor effects of proendothelin-2 (1.0 nmol kg-1), and inhibited significantly the renal and mesenteric vasoconstrictor actions of this peptide. Phosphoramidon had similar effects on the responses to proendothelin-3 (1.0 nmol kg-1), although a slight pressor effect of this peptide remained in the presence of phosphoramidon. 4. In the third experiment, it was found that phosphoramidon had no significant effect on the pressor or vasoconstrictor responses to endothelin-2 or -3 (0.1 nmol kg-1). 5. Collectively, the results indicate that the haemodynamic effects of proendothelin-2 and -3 in vivo in conscious rats are probably due to their conversion to endothelin-2 and -3, respectively, by an enzyme(s) that is inhibited by phosphoramidon. There appears to be no obvious difference between proendothelin-2, proendothelin-3 and proendothelin-1 in this respect.

Full text

PDF
584

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. D'Orléans-Juste P., Télémaque S., Claing A. Different pharmacological profiles of big-endothelin-3 and big-endothelin-1 in vivo and in vitro. Br J Pharmacol. 1991 Oct;104(2):440–444. doi: 10.1111/j.1476-5381.1991.tb12448.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Dickinson K. E., Tymiak A. A., Cohen R. B., Liu E. C., Webb M. L., Hedberg A. Vascular A10 cell membranes contain an endothelin metabolizing neutral endopeptidase. Biochem Biophys Res Commun. 1991 Apr 15;176(1):423–430. doi: 10.1016/0006-291x(91)90941-y. [DOI] [PubMed] [Google Scholar]
  3. Fukuroda T., Noguchi K., Tsuchida S., Nishikibe M., Ikemoto F., Okada K., Yano M. Inhibition of biological actions of big endothelin-1 by phosphoramidon. Biochem Biophys Res Commun. 1990 Oct 30;172(2):390–395. doi: 10.1016/0006-291x(90)90685-g. [DOI] [PubMed] [Google Scholar]
  4. Gardiner S. M., Compton A. M., Bennett T. Effects of indomethacin on the regional haemodynamic responses to low doses of endothelins and sarafotoxin. Br J Pharmacol. 1990 May;100(1):158–162. doi: 10.1111/j.1476-5381.1990.tb12069.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Gardiner S. M., Compton A. M., Bennett T., Palmer R. M., Moncada S. NG-monomethyl-L-arginine does not inhibit the hindquarters vasodilator action of endothelin-1 in conscious rats. Eur J Pharmacol. 1989 Nov 21;171(2-3):237–240. doi: 10.1016/0014-2999(89)90113-1. [DOI] [PubMed] [Google Scholar]
  6. Gardiner S. M., Compton A. M., Bennett T. Regional haemodynamic effects of endothelin-1 and endothelin-3 in conscious Long Evans and Brattleboro rats. Br J Pharmacol. 1990 Jan;99(1):107–112. doi: 10.1111/j.1476-5381.1990.tb14662.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Gardiner S. M., Compton A. M., Bennett T. Regional hemodynamic effects of endothelin-1 in conscious, unrestrained, Wistar rats. J Cardiovasc Pharmacol. 1989;13 (Suppl 5):S202–S204. doi: 10.1097/00005344-198900135-00057. [DOI] [PubMed] [Google Scholar]
  8. Gardiner S. M., Compton A. M., Bennett T. Regional hemodynamic effects of endothelin-2 and sarafotoxin-S6b in conscious rats. Am J Physiol. 1990 Apr;258(4 Pt 2):R912–R917. doi: 10.1152/ajpregu.1990.258.4.R912. [DOI] [PubMed] [Google Scholar]
  9. Gardiner S. M., Compton A. M., Kemp P. A., Bennett T. The effects of phosphoramidon on the regional haemodynamic responses to human proendothelin [1-38] in conscious rats. Br J Pharmacol. 1991 Aug;103(4):2009–2015. doi: 10.1111/j.1476-5381.1991.tb12368.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Gardiner S. M., Kemp P. A., Bennett T. Effects of the neutral endopeptidase inhibitor, SQ 28,603, on regional haemodynamic responses to atrial natriuretic peptide or proendothelin-1 [1-38] in conscious rats. Br J Pharmacol. 1992 May;106(1):180–186. doi: 10.1111/j.1476-5381.1992.tb14312.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Gardiner S. M., Kemp P. A., Bennett T., Palmer R. M., Moncada S. Nitric oxide synthase inhibitors cause sustained, but reversible, hypertension and hindquarters vasoconstriction in Brattleboro rats. Eur J Pharmacol. 1992 Mar 31;213(3):449–451. doi: 10.1016/0014-2999(92)90636-i. [DOI] [PubMed] [Google Scholar]
  12. Gardiner S. M., Kemp P. A., Compton A. M., Bennett T. Coeliac haemodynamic effects of endothelin-1, endothelin-3, proendothelin-1 [1-38] and proendothelin-3 [1-41] in conscious rats. Br J Pharmacol. 1992 Jun;106(2):483–488. doi: 10.1111/j.1476-5381.1992.tb14360.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Haywood J. R., Shaffer R. A., Fastenow C., Fink G. D., Brody M. J. Regional blood flow measurement with pulsed Doppler flowmeter in conscious rat. Am J Physiol. 1981 Aug;241(2):H273–H278. doi: 10.1152/ajpheart.1981.241.2.H273. [DOI] [PubMed] [Google Scholar]
  14. Hioki Y., Okada K., Ito H., Matsuyama K., Yano M. Endothelin converting enzyme of bovine carotid artery smooth muscles. Biochem Biophys Res Commun. 1991 Jan 31;174(2):446–451. doi: 10.1016/0006-291x(91)91436-g. [DOI] [PubMed] [Google Scholar]
  15. Hisaki K., Matsumura Y., Ikegawa R., Nishiguchi S., Hayashi K., Takaoka M., Morimoto S. Evidence for phosphoramidon-sensitive conversion of big endothelin-1 to endothelin-1 in isolated rat mesenteric artery. Biochem Biophys Res Commun. 1991 Jun 28;177(3):1127–1132. doi: 10.1016/0006-291x(91)90656-r. [DOI] [PubMed] [Google Scholar]
  16. Ikegawa R., Matsumura Y., Tsukahara Y., Takaoka M., Morimoto S. Phosphoramidon inhibits the generation of endothelin-1 from exogenously applied big endothelin-1 in cultured vascular endothelial cells and smooth muscle cells. FEBS Lett. 1991 Nov 18;293(1-2):45–48. doi: 10.1016/0014-5793(91)81149-3. [DOI] [PubMed] [Google Scholar]
  17. Le Monnier de Gouville A. C., Cavero I. Cross tachyphylaxis to endothelin isopeptide-induced hypotension: a phenomenon not seen with proendothelin. Br J Pharmacol. 1991 Sep;104(1):77–84. doi: 10.1111/j.1476-5381.1991.tb12388.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Matsumura Y., Hisaki K., Takaoka M., Morimoto S. Phosphoramidon, a metalloproteinase inhibitor, suppresses the hypertensive effect of big endothelin-1. Eur J Pharmacol. 1990 Aug 21;185(1):103–106. doi: 10.1016/0014-2999(90)90216-s. [DOI] [PubMed] [Google Scholar]
  19. Matsumura Y., Ikegawa R., Tsukahara Y., Takaoka M., Morimoto S. Conversion of big endothelin-1 to endothelin-1 by two types of metalloproteinases derived from porcine aortic endothelial cells. FEBS Lett. 1990 Oct 15;272(1-2):166–170. doi: 10.1016/0014-5793(90)80475-x. [DOI] [PubMed] [Google Scholar]
  20. Matsumura Y., Ikegawa R., Tsukahara Y., Takaoka M., Morimoto S. Conversion of big endothelin-1 to endothelin-1 by two-types of metalloproteinases of cultured porcine vascular smooth muscle cells. Biochem Biophys Res Commun. 1991 Aug 15;178(3):899–905. doi: 10.1016/0006-291x(91)90976-e. [DOI] [PubMed] [Google Scholar]
  21. Matsumura Y., Ikegawa R., Tsukahara Y., Takaoka M., Morimoto S. N-ethylmaleimide differentiates endothelin converting activity by two types of metalloproteinases derived from vascular endothelial cells. Biochem Biophys Res Commun. 1991 Jul 31;178(2):531–538. doi: 10.1016/0006-291x(91)90140-3. [DOI] [PubMed] [Google Scholar]
  22. McMahon E. G., Palomo M. A., Moore W. M., McDonald J. F., Stern M. K. Phosphoramidon blocks the pressor activity of porcine big endothelin-1-(1-39) in vivo and conversion of big endothelin-1-(1-39) to endothelin-1-(1-21) in vitro. Proc Natl Acad Sci U S A. 1991 Feb 1;88(3):703–707. doi: 10.1073/pnas.88.3.703. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Modin A., Pernow J., Lundberg J. M. Phosphoramidon inhibits the vasoconstrictor effects evoked by big endothelin-1 but not the elevation of plasma endothelin-1 in vivo. Life Sci. 1991;49(22):1619–1625. doi: 10.1016/0024-3205(91)90056-h. [DOI] [PubMed] [Google Scholar]
  24. Moncada S., Palmer R. M., Higgs E. A. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev. 1991 Jun;43(2):109–142. [PubMed] [Google Scholar]
  25. Okada K., Miyazaki Y., Takada J., Matsuyama K., Yamaki T., Yano M. Conversion of big endothelin-1 by membrane-bound metalloendopeptidase in cultured bovine endothelial cells. Biochem Biophys Res Commun. 1990 Sep 28;171(3):1192–1198. doi: 10.1016/0006-291x(90)90811-z. [DOI] [PubMed] [Google Scholar]
  26. Okada K., Takada J., Arai Y., Matsuyama K., Yano M. Importance of the C-terminal region of big endothelin-1 for specific conversion by phosphoramidon-sensitive endothelin converting enzyme. Biochem Biophys Res Commun. 1991 Oct 31;180(2):1019–1023. doi: 10.1016/s0006-291x(05)81167-2. [DOI] [PubMed] [Google Scholar]
  27. Pollock D. M., Opgenorth T. J. Evidence for metalloprotease involvement in the in vivo effects of big endothelin 1. Am J Physiol. 1991 Jul;261(1 Pt 2):R257–R263. doi: 10.1152/ajpregu.1991.261.1.R257. [DOI] [PubMed] [Google Scholar]
  28. Skolovsky M., Galron R., Kloog Y., Bdolah A., Indig F. E., Blumberg S., Fleminger G. Endothelins are more sensitive than sarafotoxins to neutral endopeptidase: possible physiological significance. Proc Natl Acad Sci U S A. 1990 Jun;87(12):4702–4706. doi: 10.1073/pnas.87.12.4702. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Takada J., Hata M., Okada K., Matsuyama K., Yano M. Biochemical properties of endothelin converting enzyme in renal epithelial cell lines. Biochem Biophys Res Commun. 1992 Feb 14;182(3):1383–1388. doi: 10.1016/0006-291x(92)91886-u. [DOI] [PubMed] [Google Scholar]
  30. Takada J., Okada K., Ikenaga T., Matsuyama K., Yano M. Phosphoramidon-sensitive endothelin-converting enzyme in the cytosol of cultured bovine endothelial cells. Biochem Biophys Res Commun. 1991 Apr 30;176(2):860–865. doi: 10.1016/s0006-291x(05)80265-7. [DOI] [PubMed] [Google Scholar]
  31. Theodorsson-Norheim E. Friedman and Quade tests: BASIC computer program to perform nonparametric two-way analysis of variance and multiple comparisons on ranks of several related samples. Comput Biol Med. 1987;17(2):85–99. doi: 10.1016/0010-4825(87)90003-5. [DOI] [PubMed] [Google Scholar]
  32. Télémaque S., D'Orléans-Juste P. Presence of a phosphoramidon-sensitive endothelin-converting enzyme which converts big-endothelin-1, but not big-endothelin-3, in the rat vas deferens. Naunyn Schmiedebergs Arch Pharmacol. 1991 Oct;344(4):505–507. doi: 10.1007/BF00172593. [DOI] [PubMed] [Google Scholar]
  33. Vijayaraghavan J., Scicli A. G., Carretero O. A., Slaughter C., Moomaw C., Hersh L. B. The hydrolysis of endothelins by neutral endopeptidase 24.11 (enkephalinase). J Biol Chem. 1990 Aug 25;265(24):14150–14155. [PubMed] [Google Scholar]
  34. Watanabe Y., Naruse M., Monzen C., Naruse K., Ohsumi K., Horiuchi J., Yoshihara I., Kato Y., Nakamura N., Kato M. Is big endothelin converted to endothelin-1 in circulating blood? J Cardiovasc Pharmacol. 1991;17 (Suppl 7):S503–S505. doi: 10.1097/00005344-199100177-00143. [DOI] [PubMed] [Google Scholar]
  35. Yanagisawa M., Kurihara H., Kimura S., Tomobe Y., Kobayashi M., Mitsui Y., Yazaki Y., Goto K., Masaki T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988 Mar 31;332(6163):411–415. doi: 10.1038/332411a0. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES